HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Atze van der Pol Selected Research

Syndecan-1 (Syndecan 1)

5/2014Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Atze van der Pol Research Topics

Disease

4Heart Failure
04/2019 - 05/2014
3Myocardial Infarction
10/2023 - 05/2014
2Fibrosis (Cirrhosis)
12/2018 - 05/2014
1Inflammation (Inflammations)
05/2014

Drug/Important Bio-Agent (IBA)

2Pyrrolidonecarboxylic Acid (Pyroglutamic Acid)IBA
12/2018 - 10/2018
2Biomarkers (Surrogate Marker)IBA
10/2018 - 05/2014
1HydrogelsIBA
10/2023
1AntioxidantsIBA
04/2019
1Glutathione (Reduced Glutathione)IBA
10/2018
1Pyroglutamate Hydrolase (5 Oxoprolinase)IBA
10/2018
1Glutathione Disulfide (GSSG)FDA LinkGeneric
10/2018
1Glutamic Acid (Glutamate)FDA Link
10/2018
1Circulating MicroRNAIBA
01/2017
1Angiotensin IIIBA
01/2017
1MicroRNAs (MicroRNA)IBA
01/2017
1Syndecan-1 (Syndecan 1)IBA
05/2014